#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Diabetes

We recommend klinickastudie

How Does Empagliflozin Stand in Terms of Diabetic Retinopathy Risk? We Have Answers Not Only from Controlled Studies but Also from Real Practice

5. 12. 2023 Source: Diabetes

Modern antidiabetics – gliflozins and glucagon-like peptide-1 receptor agonists (GLP-1RA) – significantly help improve the management of type 2 diabetes (DM2). In addition to reliable glycemic control, they offer other benefits. For example, gliflozins are known for their cardio- and renoprotective properties. GLP-1RA also reduce cardiovascular (CV) risk, though clinical evaluation (SUSTAIN-6) suggests a possible higher risk of retinopathy. This is also being investigated with gliflozins. How empagliflozin fares in this respect has been…

srdce

The Significance of Administering Gliflozins in Real Practice in Diabetics Without CV and Renal Disease

Current care standards recommend the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i,…
5. 12. 2023 Source: Diabetes
ledviny

Benefit of Empagliflozin in Patients with Chronic Kidney Disease – Results of the EMPA-KIDNEY Study

The sodium-glucose cotransporter 2 inhibitor (SGLT2i) empagliflozin is currently used to treat type…
18. 10. 2023 Source: Diabetes

Articles on this topic
srdce

Cardio-Renal-Metabolic Syndrome?

The association between type 2 diabetes (DM2) and atherosclerotic cardiovascular disease…
18. 10. 2023 Source: Diabetes
srdce a cukrovka

How does empagliflozin perform in older type 2 diabetics compared to liraglutide and sitagliptin in terms of HHF and MACE risks?

Last fall, a study was published in JAMA Network Open, focusing on older patients with type 2…
28. 8. 2023 Source: Diabetes
Nefrotiliáza - bolest pacienta

Can SGLT2 Inhibition Also Reduce the Risk of Nephrolithiasis?

Diabetes mellitus (DM) is a risk factor for the development of nephrolithiasis. Recent studies…
21. 8. 2023 Source: Diabetes
projevy dny bolest kloubů

Can Empagliflozin Also Act Against Gout?

Gliflozins, or sodium-glucose cotransporter 2 inhibitors (SGLT2i), are not only effective…
21. 7. 2023 Source: Diabetes
srdce a ledviny v anatomii člověka

How does the level of uric acid affect the incidence of cardiorenal events in patients with T2DM and CVD?

One of the post hoc analyses of the well-known EMPA-REG OUTCOME study provided data on the…
21. 7. 2023 Source: Diabetes
lékař léky pacient muž

What a General Practitioner Needs to Know About Gliflozins

The revolutionary benefits of gliflozins have completely changed the perspective on the choice…
22. 3. 2023 Source: Diabetes
náhled infografiky BI hyperglykémie

INFOGRAPHIC: Which treatment to choose in the 1st line for a patient with type 2 diabetes?

Diabetes mellitus is a complex chronic disease that requires continuous treatment and a strategy...
24. 2. 2023 Source: Diabetes
kardiorenální

Does SGLT2 Inhibitor Administration Benefit Diabetics with Low Cardiorenal Risk?

There is growing evidence of the cardiorenal protective effects of sodium-glucose…
14. 11. 2022 Source: Diabetes
různé léky

6 Possible Benefits of Adding Empagliflozin to Metformin

Currently, there is intense discussion about the advantages of sodium-glucose co-transporter 2…
14. 11. 2022 Source: Diabetes
diabetes hladiny graf

Prediabetes through the lens of current data and findings − and why hurry with intervention

Type 2 diabetes mellitus (DM2) is one of the most common causes of premature morbidity and…
27. 7. 2022 Source: Diabetes

1 2 3 4 5
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#